Platform Dermal Technology
Our continuous dermal delivery systems use an adhesive patch to deliver medicine through the skin. The delivery is a controlled, sustained release over multiple days. Starton uses proven transdermal and subcutaneous technologies to transform approved medicines – establishing superiority or new indications. Starton is focused on flattening the plasma concentration curve to reduce dose-limiting toxicity and deliver improved efficacy.
- Deliver between 50% to 90% lower AUC with equal or better tumor control vs oral
- Avoidance of toxicity due to the lower AUC will inherently lead to longer PFS due to the ability to continue treatment with the avoidance of withdrawals and dose-limiting toxicity
- Eliminate periods of subtherapeutic dosing due to short half-life
With each program, we establish an AUC target to identify the blood level (mcg/L) point estimate with oral administration where half of the dose interval is above the point estimate and half of the dose interval is below the point estimate. Using this mid-point method, the total AUC is lower than that observed with oral daily dosing which may reduce the toxicity observed with a higher AUC while maintaining efficacy.